缺氧诱导的VEGF分泌促进对双特异性T细胞参与剂的抵抗
Mengyao Xu1, Syem K Barakzai2, Raj Kumar1
1Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Signal transduction and targeted therapy
|December 18, 2025
概括
低氧导致卵巢癌中对双特异性T细胞参与因子 (BITE) 的耐药性,通过降低MUC16/CA125和增加VEGF. 将VEGF抑制剂与BITE结合起来可以克服这种抗性,改善免疫治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 高度血清性卵巢癌 (HGSOC) 是一种致命的恶性瘤,治疗选择有限,特别是在复发的环境中.
- 免疫检查点抑制剂 (ICI) 在HGSOC中表现出有限的疗效.
- 双特异性T细胞参与剂 (BITE) 提供了一种新的免疫疗法方法,通过重定向T细胞以准与瘤相关的抗原,如MUC16/CA125,这种抗原在HGSOC中过度表达.
研究的目的:
- 研究卵巢癌中对MUC16导向的BITE耐药性的机制.
- 确定潜在的治疗策略来克服BITE耐药性.
主要方法:
- 对患者样本 (血清,PBMC,) 的分析,这些样本来自于MUC16导向的BITE进展的HGSOC患者.
- 在卵巢癌细胞系中使用CRISPR/Cas9基因编辑对MUC16/CA125和VEGF进行验证.
- 对外围血液单核细胞 (PBMC) 细胞毒性的活体评估.
- 在体外研究评估缺氧和联合治疗 (VEGF抑制剂) 的影响.
主要成果:
- 在BITE上疾病的进展与MUC16/CA125下调,VEGF分泌量升高以及上皮转移到介质细胞的转变有关.
- 缺氧被确定为这些抵抗机制的关键驱动因素.
- 瘤细胞,而不是PBMCs,是抵抗的主要来源.
- 与VEGF抑制剂的联合治疗恢复了T细胞介导的细胞毒性在低氧条件下的细胞中.
结论:
- 缺氧是导致卵巢癌中BITE耐药性的关键因素.
- 在调解这种阻力方面,VEGF信号发挥着重要作用.
- 抑制VEGF,与BITE结合,代表了一种有前途的治疗策略,以提高卵巢癌免疫疗法的疗效.
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Mechanism of Angiogenesis
6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


